Newly floated biotech Hemogenyx (LSE:HEMO) linked up with Oxford University to transform treatment of blood cancers

A biotech company pioneering blood cancer treatments is to unveil a tie-up with Oxford University this week, a month after listing on the London Stock Exchange.

Hemogenyx is developing antibodies to treat leukaemia and lymphoma that it hopes will eliminate the need for chemotherapy and radiotherapy.

These treatments will target only affected cells, meaning more patients will be able to undergo bone marrow transplants, required in recurring cases of blood diseases. The link-up with Oxford will test if the process makes blood cells healthy.

Brooklyn biotech company market opening at 6th October 2017

Hemogenyx chief Dr Vladislav Sandler said the link-up could ‘completely transform’ the treatment of blood cancers. Shareholders of Hemogenyx include ‘Ivy League’ Cornell University, in New York State, where Sandler developed the pioneering technology.

The £10 million start-up is headquartered in London but its labs are in New York.


Read more:

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.

Tags: ,